Astell introduces autoclave controller software that meets FDA 21 CFR Part 11


Astell Scientific, the UK’s leading autoclave manufacturer, has launched a new software option that enables its full range of autoclaves to meet FDA 21 CFR Part 11 electronic signature regulations

FDA 21 CFR part 11 software for Astell’s autoclave range

FDA 21 CFR part 11 software for Astell’s autoclave range

The software is targeted towards customers operating in the pharmaceutical and medical manufacturing industries, but can bring benefits to a much wider range of applications should traceability be of key importance when specifying a steriliser.

The basic requirement of the Electronic Records; Electronic Signature final rule (21 CFR 11)  legislation is to ensure that any computerised system used for regulatory purposes produces electronic records that have integrity and reliability, and that electronic signatures are trustworthy and equivalent to handwritten signatures executed on paper records. Astell’s latest software combined with its advanced touchscreen controller positions the company as one of few autoclave manufacturers able to provide a solution that complies with FDA 21 CFR Part 11.

Available across both circular and square section sterilisers, the specially developed 21 CFR 11 controller software captures any change made to a cycle, option, or device parameter – which will require an electronic signature authorisation. All device changes and signatures will be electronically logged and can be recalled to provide a clear picture of user input for any given point in time. All audit trails are saved in a file format that cannot be altered in any way.

Astell spokesperson Dave Thomas commented “The introduction of FDA compliant autoclave software offers our customers the transparency and record management required by tightly regulated industries. It’s another good reason to choose Astell Scientific, and demonstrates why we remain the leaders in sterilisation.”

For more information on Astell’s FDA 21 CFR Part 11 software option, its applications or capabilities please visit

Sign up for your free email newsletter